USA— SGS North America (SGS), a multinational inspection, verification, testing, and certification organization, has announced an expansion of its biologics testing services for the US biopharmaceutical market.
This strategic shift provides the SGS Lincolnshire Centre of Excellence with new instrumentation and scientific expertise.
The centre serves pharmaceutical, biopharmaceutical, and medical device makers and producers throughout the United States.
The SGS Centre of Excellence in Lincolnshire, Illinois, is a 60,000-square-foot, cutting-edge facility.
It provides microbiology, chemistry, and biologics testing and analysis services, helping clients with both small and large molecule testing.
In addition, the site provides novel biopharmaceutical testing and product quality control solutions for all stages of the product development lifecycle.
These stages include early cell bank safety assessment and product characterization, technique development and raw material testing, and product release.
With this development, SGS has improved not only its instruments but also its specialized biologics experience and ability to enable the characterization of innovative biologics and biosimilars.
These innovations allow for analytical testing in a single facility’s discovery and commercial stages.
This comprehensive, simplified, and adaptable service delivery model is designed to fulfil the rapidly rising needs of biopharmaceutical companies aiming to speed the market launch of their products in a cost-effective manner.
Additionally, the race to market requires the ability to demonstrate regulatory compliance, which is linked to quality and safety assurance.
These issues frequently drive businesses to outsource their sophisticated and specialized testing and analytical needs.
During the event, Derick Govender, Head of SGS North America, stated that biologics are a fast-growing area of the pharmaceutical market.
Sales and development of biologics-based medicines in North America have more than doubled over the last decade.
According to Derick, SGS is expanding its biologics testing capabilities at the Lincolnshire site by adding scientific expertise and cutting-edge instrumentation to better meet the growing demand for large-molecule drug products, which is driving rapid advances in novel drug discovery.
Furthermore, SGS North America is a consortium of contract service laboratories that offer pharmaceutical development, biologics testing and characterization, biosafety, and quality control testing.
Its second Centre of Excellence, which also provides biologics testing in North America, is in Mississauga, Ontario, Canada.
SGS operates 20 laboratories in 11 countries that serve the worldwide pharmaceutical industry, making it the largest wholly-owned global network of contract analytical laboratories in this sector.
In addition to biopharmaceutical services, SGS provides solutions for medical device makers, as well as biostatistics and regulatory advice.
This broad range of services ensures that SGS remains a market leader, supporting the pharmaceutical and biopharmaceutical sectors globally.
For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook
